Aurora Cannabis Acquires Safari Flower Company for $26.5 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ACB?
Source: PRnewswire
- Acquisition Overview: Aurora Cannabis has acquired Safari Flower Company for $26.5 million through a wholly-owned subsidiary, which includes a $2 million cash payment contingent on certain conditions, demonstrating Aurora's commitment to expanding in the international medical cannabis market.
- Market Expansion Strategy: This acquisition will enhance Aurora's EU GMP-certified production capacity, expected to increase the supply of high-quality cannabis flower, thereby solidifying its leadership in high-margin and highly regulated markets.
- Financial Impact Expectations: Aurora anticipates that the transaction will yield synergies, boosting revenue and positive cash flow while enhancing Adjusted EBITDA, reflecting the company's confidence in its future financial performance.
- Global Business Strategy: Aurora aims to optimize its global supply chain through this acquisition, increasing its international market share while providing superior quality products to patients worldwide, embodying its strategic vision of 'Opening the World to Cannabis.'
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACB
Wall Street analysts forecast ACB stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.680
Low
6.28
Averages
6.77
High
7.39
Current: 3.680
Low
6.28
Averages
6.77
High
7.39
About ACB
Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The Company also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aurora Acquires Safari Flower Company for $26.5 Million
- Acquisition Overview: Aurora Cannabis has acquired Safari Flower Company for $26.5 million, which includes a $2 million cash payment, enhancing Aurora's competitive position in the international medical cannabis market.
- Market Expansion Strategy: This acquisition will enable Aurora to supply more EU GMP-compliant high-quality cannabis flower to key international markets such as Germany, Australia, Poland, and the UK, further solidifying its market leadership.
- Financial Expectations: The transaction is expected to deliver positive Adjusted EBITDA contributions in fiscal year 2027, with incremental benefits in fiscal year 2028 and beyond, indicating Aurora's confidence in future financial performance.
- Operational Efficiency Improvement: Aurora plans to leverage its plant science and operational expertise to enhance cultivation yields and commercial execution, thereby achieving higher operational efficiency in high-margin international markets.
See More
Aurora Cannabis Acquires Safari Flower Company for C$26.5M
- Acquisition Overview: Aurora Cannabis has acquired Safari Flower Company for approximately C$26.5 million, including up to C$2 million in contingent cash payments, indicating a proactive strategy in market consolidation.
- Equity and Cash Payment: Upon closing, Aurora issued 2,417,180 common shares to the selling shareholder and paid C$15 million in cash, reflecting the company's flexibility and strategic foresight in capital operations.
- Capacity Enhancement: The 59,000-square-foot EU GMP-certified indoor cultivation and manufacturing facility in Ontario will provide Aurora with incremental capacity to meet supply demands in key international markets such as Germany, Australia, Poland, and the UK.
- Future Financial Outlook: This transaction is expected to deliver positive adjusted EBITDA contributions in fiscal year 2027, with further benefits anticipated in fiscal year 2028 and beyond, thereby enhancing the company's competitive position in the market.
See More
Aurora Cannabis Acquires Safari Flower Company for $26.5 Million
- Acquisition Overview: Aurora Cannabis has acquired Safari Flower Company for $26.5 million through a wholly-owned subsidiary, which includes a $2 million cash payment contingent on certain conditions, demonstrating Aurora's commitment to expanding in the international medical cannabis market.
- Market Expansion Strategy: This acquisition will enhance Aurora's EU GMP-certified production capacity, expected to increase the supply of high-quality cannabis flower, thereby solidifying its leadership in high-margin and highly regulated markets.
- Financial Impact Expectations: Aurora anticipates that the transaction will yield synergies, boosting revenue and positive cash flow while enhancing Adjusted EBITDA, reflecting the company's confidence in its future financial performance.
- Global Business Strategy: Aurora aims to optimize its global supply chain through this acquisition, increasing its international market share while providing superior quality products to patients worldwide, embodying its strategic vision of 'Opening the World to Cannabis.'
See More
Aurora Named on Women Lead Here List for Second Year
- Recognition of Leadership: Aurora Cannabis has been named on The Globe and Mail's 2026 Women Lead Here list for the second consecutive year, highlighting the company's ongoing commitment to gender diversity at the executive level, with 50% female executives enhancing its image and ability to attract female talent.
- Cultural Development: Lori Schick, Executive VP of Human Resources at Aurora, stated that the company fosters a culture of respect, trust, and accountability, enabling female leaders to thrive and drive business forward, thereby improving overall performance and market competitiveness.
- Industry Impact: The benchmark evaluates executive teams at Canada's largest publicly traded companies using a data-driven methodology that emphasizes sustainable representation, with Aurora standing out among 85 companies, showcasing its leadership position and commitment to diversity in the industry.
- Strategic Direction: Aurora remains focused on creating an environment that encourages collaboration and diverse perspectives, which not only enhances service quality for patients and communities but also lays a solid foundation for the company's future growth.
See More
Aurora Cannabis Recognized on Women Lead Here List for Second Year
- Diversity Recognition: Aurora Cannabis has been named on The Globe and Mail's 2026 Women Lead Here list for the second consecutive year, reflecting the company's ongoing commitment to gender diversity at the executive level, with a 50% female leadership ratio that enhances its image and ability to attract female talent.
- Cultural Development: Lori Schick, Executive Vice President of Human Resources, emphasizes that Aurora fosters a culture grounded in respect, trust, and accountability, enabling female leaders to thrive and drive the company forward, which boosts employee satisfaction and teamwork.
- Industry Influence: The benchmark evaluates executive teams of Canada's largest publicly traded companies using a data-driven methodology that prioritizes measurable progress and sustained representation, with Aurora's inclusion not only enhancing its reputation in the industry but also setting a standard for others.
- Global Market Expansion: As a global leader in medical cannabis, Aurora is dedicated to improving patient lives through scientific expertise and high-quality products, continuously expanding its presence in Canada, Europe, Australia, and New Zealand, thereby solidifying its leadership position in the medical cannabis sector.
See More
Aurora Cannabis Faces Significant Challenges Ahead
- Poor Market Performance: Aurora Cannabis has lost 96% of its stock value since 2021, indicating the company's struggle to establish itself in a highly competitive market; despite cannabis being legalized in Canada since 2018, Aurora has failed to achieve significant success, highlighting deficiencies in its market strategy.
- Regulatory Change Opportunities: President Trump’s executive order reclassifying cannabis to Schedule III offers research and banking advantages, yet Aurora's negligible presence in the U.S. market limits its potential gains from these changes, constraining growth opportunities.
- Acquisition Challenges: The acquisition of Reliva, focused on CBD products, in 2020 was undermined by significant challenges in the CBD market, leading to the shutdown of operations in 2023, which underscores the difficulties and risks Aurora faces in expanding into new markets.
- Bleak Future Outlook: While a potential cannabis market revival exists, Aurora Cannabis's weak revenue growth and consistent net losses present substantial challenges for re-entering the U.S. market, prompting investors to carefully assess the company's future performance amidst these uncertainties.
See More
Aurora Acquires Safari Flower Company for $26.5 Million
- Acquisition Overview: Aurora Cannabis has acquired Safari Flower Company for $26.5 million, which includes a $2 million cash payment, enhancing Aurora's competitive position in the international medical cannabis market.
- Market Expansion Strategy: This acquisition will enable Aurora to supply more EU GMP-compliant high-quality cannabis flower to key international markets such as Germany, Australia, Poland, and the UK, further solidifying its market leadership.
- Financial Expectations: The transaction is expected to deliver positive Adjusted EBITDA contributions in fiscal year 2027, with incremental benefits in fiscal year 2028 and beyond, indicating Aurora's confidence in future financial performance.
- Operational Efficiency Improvement: Aurora plans to leverage its plant science and operational expertise to enhance cultivation yields and commercial execution, thereby achieving higher operational efficiency in high-margin international markets.
See More
Aurora Cannabis Acquires Safari Flower Company for C$26.5M
- Acquisition Overview: Aurora Cannabis has acquired Safari Flower Company for approximately C$26.5 million, including up to C$2 million in contingent cash payments, indicating a proactive strategy in market consolidation.
- Equity and Cash Payment: Upon closing, Aurora issued 2,417,180 common shares to the selling shareholder and paid C$15 million in cash, reflecting the company's flexibility and strategic foresight in capital operations.
- Capacity Enhancement: The 59,000-square-foot EU GMP-certified indoor cultivation and manufacturing facility in Ontario will provide Aurora with incremental capacity to meet supply demands in key international markets such as Germany, Australia, Poland, and the UK.
- Future Financial Outlook: This transaction is expected to deliver positive adjusted EBITDA contributions in fiscal year 2027, with further benefits anticipated in fiscal year 2028 and beyond, thereby enhancing the company's competitive position in the market.
See More
Aurora Cannabis Acquires Safari Flower Company for $26.5 Million
- Acquisition Overview: Aurora Cannabis has acquired Safari Flower Company for $26.5 million through a wholly-owned subsidiary, which includes a $2 million cash payment contingent on certain conditions, demonstrating Aurora's commitment to expanding in the international medical cannabis market.
- Market Expansion Strategy: This acquisition will enhance Aurora's EU GMP-certified production capacity, expected to increase the supply of high-quality cannabis flower, thereby solidifying its leadership in high-margin and highly regulated markets.
- Financial Impact Expectations: Aurora anticipates that the transaction will yield synergies, boosting revenue and positive cash flow while enhancing Adjusted EBITDA, reflecting the company's confidence in its future financial performance.
- Global Business Strategy: Aurora aims to optimize its global supply chain through this acquisition, increasing its international market share while providing superior quality products to patients worldwide, embodying its strategic vision of 'Opening the World to Cannabis.'
See More
Aurora Named on Women Lead Here List for Second Year
- Recognition of Leadership: Aurora Cannabis has been named on The Globe and Mail's 2026 Women Lead Here list for the second consecutive year, highlighting the company's ongoing commitment to gender diversity at the executive level, with 50% female executives enhancing its image and ability to attract female talent.
- Cultural Development: Lori Schick, Executive VP of Human Resources at Aurora, stated that the company fosters a culture of respect, trust, and accountability, enabling female leaders to thrive and drive business forward, thereby improving overall performance and market competitiveness.
- Industry Impact: The benchmark evaluates executive teams at Canada's largest publicly traded companies using a data-driven methodology that emphasizes sustainable representation, with Aurora standing out among 85 companies, showcasing its leadership position and commitment to diversity in the industry.
- Strategic Direction: Aurora remains focused on creating an environment that encourages collaboration and diverse perspectives, which not only enhances service quality for patients and communities but also lays a solid foundation for the company's future growth.
See More
Aurora Cannabis Recognized on Women Lead Here List for Second Year
- Diversity Recognition: Aurora Cannabis has been named on The Globe and Mail's 2026 Women Lead Here list for the second consecutive year, reflecting the company's ongoing commitment to gender diversity at the executive level, with a 50% female leadership ratio that enhances its image and ability to attract female talent.
- Cultural Development: Lori Schick, Executive Vice President of Human Resources, emphasizes that Aurora fosters a culture grounded in respect, trust, and accountability, enabling female leaders to thrive and drive the company forward, which boosts employee satisfaction and teamwork.
- Industry Influence: The benchmark evaluates executive teams of Canada's largest publicly traded companies using a data-driven methodology that prioritizes measurable progress and sustained representation, with Aurora's inclusion not only enhancing its reputation in the industry but also setting a standard for others.
- Global Market Expansion: As a global leader in medical cannabis, Aurora is dedicated to improving patient lives through scientific expertise and high-quality products, continuously expanding its presence in Canada, Europe, Australia, and New Zealand, thereby solidifying its leadership position in the medical cannabis sector.
See More
Aurora Cannabis Faces Significant Challenges Ahead
- Poor Market Performance: Aurora Cannabis has lost 96% of its stock value since 2021, indicating the company's struggle to establish itself in a highly competitive market; despite cannabis being legalized in Canada since 2018, Aurora has failed to achieve significant success, highlighting deficiencies in its market strategy.
- Regulatory Change Opportunities: President Trump’s executive order reclassifying cannabis to Schedule III offers research and banking advantages, yet Aurora's negligible presence in the U.S. market limits its potential gains from these changes, constraining growth opportunities.
- Acquisition Challenges: The acquisition of Reliva, focused on CBD products, in 2020 was undermined by significant challenges in the CBD market, leading to the shutdown of operations in 2023, which underscores the difficulties and risks Aurora faces in expanding into new markets.
- Bleak Future Outlook: While a potential cannabis market revival exists, Aurora Cannabis's weak revenue growth and consistent net losses present substantial challenges for re-entering the U.S. market, prompting investors to carefully assess the company's future performance amidst these uncertainties.
See More
